Exelixis Moves Into RNA-Modifying Cancer Therapy With Storm Pact
Deal Snapshot: In addition to investigating the ADAR1 target with the UK biotech, Exelixis also has optioned a second candidate for non-Hodgkin’s lymphoma under its 2019 deal with Aurigene.
You may also be interested in...
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.
The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.
AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.